Why Valeant Pharmaceuticals Intl Inc. Surged Almost 10% Today

Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX) is clearly making progress under its new CEO, but there are still many hurdles to overcome.

| More on:
The Motley Fool

With another very strong day for Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX) shares, it is only natural for investors to wonder what’s up.

I mean, with the stock surging almost 10% today and trading near 52-week highs, it is clearly being bid up by investors who are becoming more bullish on Valeant’s business and future.

The stock has rallied 35% year to date in what is becoming a great rally for a stock so tarnished by its past.

Let’s recall how we got here.

In early 2015, the company was on dangerous path that the market only saw as positive, with its stock flying high, hitting levels north of $350 and continuing to experience tremendous growth by acquisition.

The problem was, this was not a sustainable strategy, and while this aggressive acquisition strategy could not even be stopped by a debt-to-capital ratio of 70% and a debt-to-EBITDA ratio of over six times, one day it did stop.

Valeant’s fall was dramatic, as its pricing practices came under question, an SEC investigation was initiated, and its heavy debt load threatened its survival.

By the end of 2015, the stock was pretty much worth half of what it was at its highs, and it subsequently continued to fall and settle at levels between $20 and $40.

Today, the shares are rallying off the company’s announcement that it will be distributing Vyzulta, for the treatment of glaucoma, to U.S. wholesale pharmaceutical distributors.

The stock appears to be cheap, trading at almost eight times next year’s consensus earnings, but remember, revenue and earnings have been declining. And the overhang on the stock remains.

The following reasons explain why I think investors should be very cautious about investing in Valeant.

There remains an overhang on the stock and the company in the form of an SEC investigation and investigations into pricing practices. We don’t know what the outcome will be, and we don’t know what penalties or fines will be imposed if the company is found to be guilty.

And while Valeant has been working on reducing debt, the company’s debt level is still high at $26 billion for a debt-to-total capitalization ratio of a whopping 84%.

These factors increase the risk profile of the company and the shares enough to warrant taking a wait-and-see approach.

On the positive side, the company has beat expectations in the last two quarters, which is a good sign.

Also, the new CEO appears to be doing a good job in reducing the company’s risk profile by investing in pharmaceuticals that have passed regulatory hurdles and that have smaller niche markets.

This strategy reduces approval risk and reduces the potential for competition from the big pharmaceutical companies, which tend to focus on bigger market drugs.

In closing, in my view, and despite the run-up Valeant has had recently, I see too many items on the risk side of the equation.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Karen Thomas does not own shares in any of the companies listed in this article. Tom Gardner owns shares of Valeant Pharmaceuticals. The Motley Fool owns shares of Valeant Pharmaceuticals.

More on Investing

A cannabis plant grows.
Cannabis Stocks

Canopy Growth Stock Is Rising But I’m Worried About This One Thing

Canopy Growth stock is soaring as the legalization effort makes real progress in both Germany and the United States.

Read more »

young woman celebrating a victory while working with mobile phone in the office
Investing

3 Roaring Stocks to Hold for the Next 20 Years

These top TSX stocks are excellent long-term buys, given their multi-year growth potential and solid underlying businesses.

Read more »

Two seniors float in a pool.
Dividend Stocks

TFSA: How to Earn $1,890 in Annual Tax-Free Income

Plunk these investments into your TFSA to earn passive income and avoid the taxman.

Read more »

grow dividends
Investing

Here’s My Top 3 TSX Stocks to Buy Right Now

Even though the TSX has been rising, there are still some good bargains out there. Here are three top compounding…

Read more »

Target. Stand out from the crowd
Investing

Prediction: This Canadian Growth Stock Could Double by 2030

Alimentation Couche-Tard (TSX:ATD) is a top growth stock that could do well over the next six or so years.

Read more »

Businessman holding AI cloud
Tech Stocks

Could Investing $20,000 in Nvidia Make You a Millionaire?

Nvidia stock has made investors millionaires in the last 10 years. Is it too late to invest to become a…

Read more »

Engineers walk through a facility.
Dividend Stocks

1 TSX Stock I Wouldn’t Touch With a 10-Foot Pole

AtkinsRéalis (TSX:ATRL) is one TSX stock I'd never invest in.

Read more »

money cash dividends
Stocks for Beginners

Have $500? 3 Absurdly Cheap Stocks Long-Term Investors Should Buy Right Now

If you're looking for cheap stocks, these three have a huge future ahead of them, all while costing far less…

Read more »